Drug
IMU-838
IMU-838 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
1(25%)
Results Posted
100%(2 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(2)
Terminated(1)
Detailed Status
Completed2
Terminated1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
completed250%
terminated125%
active_not_recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
completedphase_2
A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
NCT04379271
active_not_recruitingphase_2
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
NCT05054140
terminatedphase_2
Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
NCT03341962
completedphase_2
IMU-838 and Oseltamivir in the Treatment of COVID-19
NCT04516915
Clinical Trials (4)
Showing 4 of 4 trials
NCT04379271Phase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
NCT05054140Phase 2
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
NCT03341962Phase 2
Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
NCT04516915Phase 2
IMU-838 and Oseltamivir in the Treatment of COVID-19
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4